Published in Eur J Cancer on September 01, 2000
Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group project. Haematologica (2012) 0.93
Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. Br J Cancer (2009) 0.83
Primary adrenal lymphoma with secondary central nervous system involvement: a case report and review of the literature. Turk J Haematol (2013) 0.81
A rare presentation of follicular lymphoma: cerebellar involvement, successfully treated with a combination of radiotherapy and chemotherapy. Cancer Res Treat (2013) 0.81
Pineal Diffuse Large B-Cell Lymphoma Concomitant With Pituitary Prolactinoma: Possible Correlation Between 2 Distinguished Pathologies: A Case Report. Medicine (Baltimore) (2016) 0.75
A novel orally available inhibitor of focal adhesion signaling increases survival in a xenograft model of diffuse large B-cell lymphoma with central nervous system involvement. Haematologica (2013) 0.75
Paraplegia: an unusual presentation of follicular lymphoma. Indian J Hematol Blood Transfus (2014) 0.75
Multifocal extranodal lymphoma: A case report. Medicine (Baltimore) (2016) 0.75
Long-term remission of subcutaneous panniculitis-like T-cell lymphoma with central nervous system involvement: A case report. Oncol Lett (2016) 0.75
Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma. Neuro Oncol (2015) 0.75
Follicular lymphoma presenting with leptomeningeal disease. Case Rep Hematol (2014) 0.75
Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network. Haematologica (2015) 0.75
T-cell lymphoma mimicking schwannoma of a cervical nerve root. Neurosurg Rev (2008) 0.75
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
[Treatment of spinal cord compression caused by malignant disease]. Tidsskr Nor Laegeforen (1991) 2.04
[Treatment with growth factors and cytokines in hematologic diseases]. Tidsskr Nor Laegeforen (1996) 2.03
Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines. Bone Marrow Transplant (2001) 1.66
Trends in incidence of brain and central nervous system tumors in Norway, 1970-1999. Neuroepidemiology (2004) 1.62
A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol (1997) 1.59
Clinical stage I and II Hodgkin's disease: long-term results of therapy without laparotomy. Experience at one institution. Ann Oncol (1996) 1.45
Persistent changes in the immune system 4-10 years after ABMT. Bone Marrow Transplant (1999) 1.44
[High-dose autologous stem cell support in malignant diseases--an established method, uncertain indication]. Tidsskr Nor Laegeforen (1994) 1.39
Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol (2002) 1.37
Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol (1993) 1.35
Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand (2010) 1.26
Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys (1999) 1.18
A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation. Bone Marrow Transplant (2004) 1.14
DNA synthesis in human bone marrow is circadian stage dependent. Blood (1991) 1.10
Functional properties of CD19+ B lymphocytes positively selected from buffy coats by immunomagnetic separation. Eur J Immunol (1990) 1.08
Pulmonary toxicity of cytotoxic and immunosuppressive agents. A review. Acta Oncol (1990) 1.07
Familial occurrence of papillary thyroid carcinoma. Cancer (1980) 1.06
Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study. Br J Cancer (2009) 1.06
Knowledge of and attitudes toward complementary and alternative therapies; a national multicentre study of oncology professionals in Norway. Eur J Cancer (2004) 1.05
Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin's disease: an echocardiographic study. Heart (1996) 1.03
Transforming growth factor type beta (TGF beta) inhibits G1 to S transition, but not activation of human B lymphocytes. Exp Cell Res (1987) 1.02
Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol (2002) 1.02
DNA synthesis and ploidy in non-Hodgkin's lymphomas demonstrate intrapatient variation depending on circadian stage of cell sampling. Cancer Res (1993) 1.02
Impact of intraoperative MRI on the surgical results for high-grade gliomas. Minim Invasive Neurosurg (2005) 0.99
High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression. J Neurooncol (1992) 0.95
Cardiopulmonary sequelae after treatment for Hodgkin's disease: increased risk in females? Ann Oncol (1996) 0.95
Post-treatment parenthood in Hodgkin's lymphoma survivors. Br J Cancer (2007) 0.94
Bone metastasis. Prognosis, diagnosis and treatment. Acta Radiol Oncol (1987) 0.93
Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol (2004) 0.93
DNA cell cycle distribution and glutathione (GSH) content according to circadian stage in bone marrow of cancer patients. Br J Cancer (1992) 0.91
Late medical complications and fatigue in Hodgkin's disease survivors. J Clin Oncol (2001) 0.89
Hodgkin's disease in a national and hospital population: trends over 20 years. Eur J Cancer (1997) 0.89
Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin's lymphoma. Int J Cancer (2000) 0.89
Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year? Bone Marrow Transplant (1999) 0.88
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol (2007) 0.87
Prognostic factors for glioblastoma multiforme--development of a prognostic index. Acta Oncol (1996) 0.87
Effects of benzaldehyde on survival and cell-cycle kinetics of human cells cultivated in vitro. Eur J Cancer Clin Oncol (1983) 0.87
High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant (2001) 0.87
Prevalence of Norwegian patients diagnosed with childhood cancer, their working ability and need of health insurance benefits. Acta Oncol (2007) 0.86
Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients. Cancer Chemother Pharmacol (1999) 0.86
Colony-forming unit-granulocyte-macrophage and DNA synthesis of human bone marrow are circadian stage-dependent and show covariation. Blood (1992) 0.86
Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway. Support Care Cancer (2004) 0.86
Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol (2007) 0.86
Cause of death and long-term survival in patients with neuro-epithelial brain tumours: a population-based study. Eur J Cancer (2003) 0.85
Socio-medical situation for long-term survivors of Hodgkin's disease: a survey of 459 patients treated at one institution. Eur J Cancer (1998) 0.85
Disseminated intravascular coagulation in patients with meningococcal infection: laboratory diagnosis and prognostic factors. Scand J Infect Dis (1978) 0.84
Inhibition of polyphosphoinositide breakdown and c-myc induction accompanying inhibition of human B-cell activation by two monoclonal antibodies against the leucocyte common antigen (CD45). Scand J Immunol (1990) 0.84
A 10-year experience with splenectomy in patients with malignant non-Hodgkin's lymphoma at the Norwegian Radium Hospital. Cancer (1994) 0.84
Posterior fossa medulloblastoma in children and young adults (0-19 years): survival and performance. Childs Nerv Syst (1999) 0.84
Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol (2004) 0.84
Radical radiation treatment of invasive and locally advanced bladder carcinoma in elderly patients. Br J Urol (1991) 0.83
Entourage: the immune microenvironment following follicular lymphoma. Blood Cancer J (2012) 0.83
Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. Br J Cancer (2009) 0.83
ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience. Eur J Haematol (2004) 0.83
Loss of chromosome 11q21-23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma. Br J Cancer (2001) 0.83
Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas. Leukemia (2006) 0.83
c-MYC, RB-1, TP53, and centromere 8 and 17 copy number in B-cell non-Hodgkin's lymphomas assessed by dual-color fluorescence in situ hybridization. Cytometry (1999) 0.83
Activation of human B cells: alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells. J Immunol (1987) 0.83
Triglyceride lipase activity and human platelets. Thromb Haemost (1979) 0.82
Demecolcin and vinblastine sulphate as stathmokinetic agents for different tissues of the hairless mouse. Pathol Eur (1975) 0.82
Lung function impairment in long-term survivors of Hodgkin's disease. Ann Oncol (1995) 0.81
CD34(+) cell enrichment depletes atypical CD30(+) cells from PBPC grafts in patients with HD. Cytotherapy (2001) 0.81
Pneumothorax during combination chemotherapy. Cancer (1981) 0.81
Simultaneous assessment of chromatin structure, DNA content, and antigen expression by dual wavelength excitation flow cytometry. Cytometry (1991) 0.81
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant (2012) 0.81
Tissue specificity of the epidermal chalones. Virchows Arch B Cell Pathol (1975) 0.81
High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells. Bone Marrow Transplant (2001) 0.80
Intracavity fractionated balloon brachytherapy in glioblastoma. Acta Neurochir (Wien) (1999) 0.80
Prognostic factors in malignant gliomas with special reference to intra-arterial chemotherapy. Acta Oncol (1993) 0.80
Late medical sequelae after therapy for supradiaphragmatic Hodgkin's disease. Acta Oncol (1999) 0.80
Glutathione content in human bone marrow and circadian stage relation to DNA synthesis. J Natl Cancer Inst (1991) 0.80
Downregulation of c-myc RNA is not a prerequisite for reduced cell proliferation, but is associated with G1 arrest in B-lymphoid cell lines. Exp Cell Res (1987) 0.80
The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomas. Int J Cancer (1987) 0.80
Effects of benzaldehyde on protein metabolism-of human cells cultivated in vitro. Eur J Cancer Clin Oncol (1983) 0.80
Anticipatory nausea and vomiting in cancer patients. J Consult Clin Psychol (1991) 0.80
Primary malignant lymphoma of the brain. A report of 24 cases from the Norwegian Radium Hospital. Acta Oncol (1992) 0.79
Triggering of neoplastic B cells via surface IgM and the cell surface antigens CD20 and CDw40. Responses differ from normal blood B cells and are restricted to certain morphologic subsets. Int J Cancer (1988) 0.79
The CUP trial: a randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol (2000) 0.79
Temporary ischaemia induced by degradable starch microspheres. Possible thrombogenic effects in vivo and in vitro. Acta Radiol Oncol (1981) 0.79
A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas. Eur J Cancer (1998) 0.78
Tumour cell proliferation, but not apoptosis, predicts survival in B-cell non-Hodgkin's lymphomas. Br J Cancer (1998) 0.77
Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients. Eur J Haematol Suppl (2001) 0.77
Fat replacement of Hodgkin disease of bone marrow after chemotherapy: report of three cases. Skeletal Radiol (1996) 0.77
Treatment-related premature ovarian failure as a long-term complication after Hodgkin's lymphoma. Ann Oncol (2006) 0.77
Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant (1998) 0.77
Bone-marrow MR imaging before and after autologous marrow transplantation in lymphoma patients without known bone-marrow involvement. Acta Radiol (1997) 0.77
Purging of tumor cells from leukapheresis products: experimental and clinical aspects. J Hematother (1996) 0.77
Successful pregnancy following treatment of primary malignant lymphoma of the uterine cervix. Gynecol Oncol (1990) 0.77